NCT02682953

Brief Summary

This is a pilot study to evaluate the efficacy of hyperbaric oxygen therapy (HBO2) for mobilizing hematopoietic progenitor cells from bone marrow to blood. These cells are needed for patients to undergo bone marrow transplantation and some patients fail to respond to current best chemotherapy. HBO2 has been shown to trigger stem cell mobilization in other patient populations and we plan to investigate whether this intervention can act in concert with chemotherapeutic agents to allow poor mobilizer patients to achieve successful bone marrow transplantation. Twenty patients will be identified by participating hematologists who have failed to respond adequately to chemotherapy. When it is deemed appropriate to attempt an additional stem cell mobilization protocol, these patients will be administered chemotherapy as determined by their primary treating hematologist and additionally receive daily HBO2 (2.5 atmospheres absolute \[ATA\] for 90 minutes) for 3-8 days. At intervals, blood samples will be obtained as is the normal transplantation protocol practice to assess whether adequate stem cells are present in blood for the patient to proceed with transplantation. The project is anticipated to take one year to complete.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Oct 2015

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2015

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

February 9, 2016

Completed
8 days until next milestone

First Posted

Study publicly available on registry

February 17, 2016

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2017

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2017

Completed
Last Updated

December 11, 2019

Status Verified

December 1, 2019

Enrollment Period

1.3 years

First QC Date

February 9, 2016

Last Update Submit

December 9, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of patients who adequately mobilize stem cells to undergo bone marrow transplantation.

    Among entered patients, the number who adequately mobilization of stem cells to proceed with bone marrow transplantation

    1-2 years

Study Arms (1)

Hyperbaric oxygen therapy

EXPERIMENTAL

Exposure to oxygen at 2.4 atmospheres absolute for 90 minutes/day for 3 to 5 days

Drug: NeupogenProcedure: Hyperbaric oxygen therapyDrug: Plerixafor

Interventions

Pharmacological agents often used for stem cell mobilization will be utilized in this study.

Also known as: Plerixafor
Hyperbaric oxygen therapy

Exposure to oxygen at 2.4 atmospheres absolute for 90 minutes/day for 3 to 5 days

Hyperbaric oxygen therapy

Pharmacological agents often used for stem cell mobilization will be utilized in this study.

Hyperbaric oxygen therapy

Eligibility Criteria

Age21 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Clinical indication for hematopoietic stem cell transplantation.
  • Those failing to achieve an adequate collection of progenitor cells with standard chemotherapy treatment to safely perform hematopoietic stem cell transplantation.

You may not qualify if:

  • Diabetes mellitus
  • Renal or other organ transplantation and on immunosuppressive agents
  • NYHA Class III or IV heart failure
  • Liver cirrhosis
  • HIV infection and/or AIDS
  • Seizure disorder and not taking anti-seizure medications
  • Asthma/bronchospasm not resolvable with inhaled bronchodilators
  • Eustachian tube dysfunction and inability to equalization of pressure across the middle ears
  • Confinement anxiety not controlled with oral benzodiazepine therapy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Maryland Medical Center

Baltimore, Maryland, 21201, United States

Location

MeSH Terms

Conditions

Multiple MyelomaLymphoma

Interventions

FilgrastimplerixaforHyperbaric Oxygenation

Condition Hierarchy (Ancestors)

Neoplasms, Plasma CellNeoplasms by Histologic TypeNeoplasmsHemostatic DisordersVascular DiseasesCardiovascular DiseasesParaproteinemiasBlood Protein DisordersHematologic DiseasesHemic and Lymphatic DiseasesHemorrhagic DisordersLymphoproliferative DisordersImmunoproliferative DisordersImmune System DiseasesLymphatic Diseases

Intervention Hierarchy (Ancestors)

Granulocyte Colony-Stimulating FactorColony-Stimulating FactorsGlycoproteinsGlycoconjugatesCarbohydratesHematopoietic Cell Growth FactorsCytokinesIntercellular Signaling Peptides and ProteinsPeptidesAmino Acids, Peptides, and ProteinsProteinsBiological FactorsOxygen Inhalation TherapyRespiratory TherapyTherapeutics
0

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

February 9, 2016

First Posted

February 17, 2016

Study Start

October 1, 2015

Primary Completion

February 1, 2017

Study Completion

August 1, 2017

Last Updated

December 11, 2019

Record last verified: 2019-12

Data Sharing

IPD Sharing
Will share

Data on stem cell changes with treatment

Locations